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Abstract
Neurodegenerative diseases are characterized by a progressive loss of neurons that leads to a broad 
range of disabilities, including severe cognitive decline and motor impairment, for which there are 
no effective therapies. Several lines of evidence support a putative therapeutic role of nuclear 
receptors (NRs) in these types of disorders. NRs are ligand-activated transcription factors that 
regulate the expression of a wide range of genes linked to metabolism and inflammation. Although 
the activation of NRs in animal models of neurodegenerative disease exhibits promising results, 
the translation of this strategy to clinical practice has been unsuccessful. In this review we discuss 
the role of NRs in neurodegenerative diseases in light of preclinical and clinical studies, as well as 
new findings derived from the analysis of transcriptomic databases from humans and animal 
models. We discuss the failure in the translation of NR-based therapeutic approaches and consider 
alternative and novel research avenues in the development of effective therapies for 
neurodegenerative diseases.
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1. INTRODUCTION
Neurodegenerative diseases are characterized by progressive neuronal loss that leads to a 
broad range of clinical manifestations typically associated with severe motor disability, 
cognitive decline, and dementia. Currently, more than 40 million people worldwide are 
affected by these disorders, and since age is the major risk factor for most neurodegenerative 
diseases, the aging of the global population will further increase the burden of these 
disorders (1). Available therapeutic strategies are limited and mainly focus on 
symptomatology, as they are not able to delay the underlying progressive loss of neurons. 
Therefore, the development of novel and effective therapies to treat these diseases is urgent. 
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Several lines of evidence have established an association between neurodegenerative 
diseases and type II nuclear receptors (NRs), namely the retinoid X receptor (RXR), the 
retinoic acid receptor (RAR), the liver X receptor (LXR), the peroxisome proliferator-
activated receptors (PPARs), and, more recently, the nuclear receptor related-1 protein 
(Nurr1) (2, 3). NRs belong to a superfamily of ligand-activated transcription factors that 
regulate the expression of a wide range of genes. In general, NR activity modulates energy 
and lipid homeostasis in response to environmental and dietary changes (4). Over the past 
two decades, a myriad of studies have built a 
robustbodyofevidenceshowingthattheactivationofNRsinanimalmodelsofneurodegenerative 
diseases exerts salutary effects (3). However, the translation of this strategy to human 
patients has been unsuccessful in several clinical trials that have failed to show therapeutic 
efficacy. Given the promising preclinical results, it remains unclear why the clinical 
translation of NR activation has been unsuccessful. In this review, we summarize the role of 
NRs in neurodegenerative diseases, considering both preclinical and clinical data. Our 
objectives are to better understand the reasons 
forfailureinthetranslationofthistherapeuticstrategyandtosuggestalternativeresearchavenues, in 
the context of NR signaling, that could have a better chance to succeed in patients suffering 
from these diseases.
1.1. Neurodegenerative Diseases
Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and 
amyotrophic lateral sclerosis (ALS) are among the most prevalent neurodegenerative 
diseases. These disorders exhibit a marked neuroinflammatory component and are 
predominantly associated with the abnormal accumulation of proteins such as β-amyloid 
(Aβ), microtubule-associated protein tau, α-synuclein (α-syn), huntingtin (htt), superoxide 
dismutase 1 (SOD1), and TDP43.
1.1.1. Alzheimer’s disease.—AD is characterized by the accumulation of Aβ peptides 
generated from the sequential cleavage of amyloid precursor protein (APP) by β and γ 
secretases, giving rise to mainly Aβ peptides that are either 40 or 42 amino acids in length. 
The self-aggregating Aβ42 peptide drives the generation of oligomeric species, which 
ultimately results in Aβ deposition in the brain parenchyma where they form amyloid 
plaques (5, 6). The accumulation of amyloid peptides and deposits leads to 
neuroinflammatory processes, hyperphosphorylation of the tau protein (p-tau), and 
subsequent neurodegeneration (5). Although the majority of AD patients exhibit the 
sporadic, late-onset disease, thought to be due to the impairment of Aβ clearance 
mechanisms, a subset of patients inherit familial AD, which is due to genetic variants that 
favor the generation of Aβ1–42 species (5, 7).
1.1.2. Parkinson’s disease.—The predominant form of PD is sporadic with only about 
10% of cases being inherited (8). Traditionally, PD has been diagnosed based on the 
presence of Lewy bodies composed of misfolded and/or aggregated forms of the protein α-
syn, which is associated with the progressive loss of vulnerable dopaminergic neurons, 
primarily in the substantia nigra. Specific point mutations in the α-syn gene, SNCA, as well 
as SNCA multiplications, have been linked to inherited forms of PD (9). Along with protein 
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misfolding, several other pathological mechanisms seem to underlie PD pathology, such as 
mitochondrial dysfunction, endoplasmic reticulum (ER) stress, aberrant ubiquitin, and 
chaperon-mediated autophagy clearance (10, 11).
1.1.3. Huntington’s disease.—HD is a rare inherited autosomal-dominant disorder 
that results from the presence of expanded CAG repeats in the gene encoding htt. The CAG 
repeats give rise to mutant forms of htt (mhtt) harboring a polyglutamine (polyQ) domain, 
which induces conformational changes, resulting in intracellular aggregates (12). Although 
the exact mechanisms by which intracellular polyQ-htt aggregates cause neuronal death 
remain unclear, it has been suggested that transcriptional deregulation due to sequestration 
of critical transcription factors, such as p53, SP1, and CBP, by intracellular mhtt aggregates 
might play an important role (13).
1.1.4. Amyotrophic lateral sclerosis.—ALS is characterized by the degeneration of 
large motor neurons in the brain and spinalcord, and has a multifaceted etiology that 
includes impaired messenger RNA (mRNA) stability and microRNA processing; altered 
axonal trafficking of mRNA; dysregulated transcription due to mutations in genes such as 
TDP43, FUS, and C9ORF72; glutamate mediated excitotoxicity; and impaired 
neurotransmitter release (14). Additionally, mutations in the SOD1 gene, including G93A, 
result in the misfolding and aggregation of the mutant SOD1 protein within motor neurons, 
which leads to ER stress, mitochondrial dysfunction, and further disruption of axonal 
transport, which in turn results in neuronal loss. Similar to HD, neurodegeneration in ALS is 
also associated with dysregulated transport of ubiquitinated proteins to the proteosome and 
impaired proteosome/autophagosome functions (14, 15).
1.2. Nuclear Receptors
The type II NRs compose a family of ligand-activated transcription factors that form 
obligate heterodimerswithRXR.Thedimericreceptorbindstosequence-
specificDNAresponseelements that are positioned in the enhancer and promoter regions of 
their target genes, and act to directly regulate gene transcription (16) (Figure 1). Importantly, 
NR heterodimers can be considered permissive when the heterodimer is activated by ligation 
of either member of the receptor pair, and when it is simultaneously ligated, it can respond 
in an additive or synergistic fashion. This is the case for LXR, PPAR, and Nurr1 
heterodimers with RXR. On the other hand, heterodimers of 
RARwithRXRareconsideredtobeconditionallypermissivesinceitisthebindingofaRARligand 
that activates the dimer and subsequently allows the binding of RXR ligands, which 
increases the transcriptional potential of RAR. This type of heterodimer is not activated by 
RXR ligands alone; there are also nonpermissive RXR heterodimers, such as the thyroid 
hormone receptor, which respond only to ligands of the nonpermissive binding partner and 
not RXR (17, 18). In the absence of ligand binding, RXR heterodimers are bound to DNA 
and inhibit transcription through their interaction with corepressor complexes (16, 18, 19). 
Interestingly, monomers of PPARγ, LXRs, and Nurr1 are also able to repress gene 
expression, namely of nuclear factor-κB (NF-κB) target genes, which inhibit the 
inflammatory response (19, 20).
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1.2.1. RXR.—The three RXR, isoforms RXRα, RXRβ, and RXRγ, are expressed in 
several regions of the adult brain in sex- and isoform-specific patterns (21, 22). The roles of 
RXRs are very diverse owing to their ability to dimerize with other type II NRs, activating 
many different genes and pathways.Although9-cis- retinoic acid was initially proposed to be 
the endogenous ligand for RXR, several inconsistencies have raised doubts about this 
assumption, and the primary endogenous or natural ligands for these receptors remain 
unclear. Finally, n-3 polyunsaturated fatty acids (PUFAs), such as docosahexaenoic acid, 
have been identified as RXR ligands, as have 9-cis-13,14dihydroretinoic acid, and phytanic 
acid (23, 24).
1.2.2. RAR.—Similar to RXR, the three RAR isoforms, RARα, RARβ, and RARγ, are 
expressed throughout the adult brain in sex- and isoform-dependent, region-specific patterns 
(21, 22). RARs bind to all-trans-retinoic acid (RA), which serves as its principal ligand, but 
also interact with 9cis-retinoic acid (25). Mice lacking RARβ exhibit impaired long-term 
depression and long-term potentiation of synaptic transmission (26), and the knockout of 
RARα in mice revealed that this 
receptorisrequiredforthehomeostaticsynapticplasticity,i.e.,theabilityofneuronstoadjusttheir 
own excitability to maintain the stability of circuit activity, mediated by RA (27). Aside 
from their role in cognition, RARs also seem to play a role in motor function in coordination 
with RXR (25). It has also been suggested that RARs are important regulators of sleep and 
the circadian cycle (28).
1.2.3. LXR.—Although both LXR isoforms, LXRα and LXRβ, are expressed in the 
brain, LXRβ exhibits a more extensive expression pattern in this organ (29). LXRs regulate 
lipid homeostasis and inflammation and are activated by endogenous oxysterols derived 
from cholesterol. The critical role of LXR in the brain is demonstrated by genetic models 
lacking these receptors. LXR double-knockout mice exhibit several brain abnormalities, 
including excessive lipid deposition, astrogliosis, and extensive neuronal loss (30). LXRβ-
specific knockout mice also exhibit lipid accumulation, motor neuron degeneration, and 
astrocytic proliferation (31).
1.2.4. PPARs.—The three PPAR isoforms, PPARα, PPARβ/δ, and PPARγ, are 
expressed throughout the brain, and it seems that PPARs are more highly expressed in 
neurons than in other cell types (32). Endogenous and natural ligands of PPARs include 
mainly PUFAs and their derivatives, as well as other lipids (33). PPARγ has an important 
role in the anti-inflammatory response, neuroprotection, and neuronal differentiation and 
function (34, 35). PPARα has been linked to neuroprotection and anti-inflammatory 
responses (36), as well as to the regulation of energy homeostasis (37) and synaptic function 
(38). Finally, PPARβ/δ is involved in astroglial and oligodendrocyte differentiation, 
myelination, and neuroprotection (39).
1.2.5. Nurr1.—Nurr1 is a member of the NR4A family, and, unlike type II receptors, it 
can directly bind to DNA and regulate transcription as a monomer or homodimer, or as a 
heterodimer with RXR (40). Nurr1 is expressed at high levels in the brain (41), and studies 
using Nurr1 knockout and conditional knockout mice have established the critical role of 
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Nurr1 in the generation and development of dopaminergic neurons as well as in the 
maintenance and survival of these cells (42–44). It is still not clear whether Nurr1 interacts 
with an endogenous or natural ligand; however, the transcriptional activity of the 
Nurr1:RXR heterodimer can be stimulated by ligands interacting with RXR (45).
2. THE ROLE OF NUCLEAR RECEPTORS IN NEURODEGENERATIVE 
DISEASES
Although the therapeutic role of NRs in neurodegenerative diseases has been extensively 
characterized by numerousstudies usingdifferent animal models and ligands, NR agonists 
have generally failed to demonstrate clinical efficacy. In this section, we review preclinical 
evidence for a neuroprotective role of NR activation in different animal models (summarized 
in Table 1), systematize crucial mechanisms underlying their effects (Figure 2), and 
summarize the clinical outcomes arising from this therapeutic strategy (Table 1). We also 
review studies and analyze transcriptomic databases containing data from the central 
nervous system of human patients to better understand the role of NRs in these pathologies. 
The expression profile of NRs as well as the levels of endogenous or natural ligands 
observed in these patients is summarized in Table 2.
2.1. RXR in Alzheimer’s Disease
RXRα Mrna and protein expression levels are increased in the brains of AD patients (Table 
2), which is evident at very early stages of dementia in the temporal gyrus and hippocampus 
and persists throughout the disease (46). The analysis of global gene expression in neurons 
obtained from several areas in the brains of AD patients indicates that the neuronal 
expression of RXRα is not altered (Table 2), suggesting that the increase in RXRα 
expression is likely to occur in non-neuronal cells. The RXR agonist bexarotene was initially 
described to increase astrocytic apolipoprotein E (ApoE) expression and ApoE-mediated Aβ 
clearance, as it rapidly lowered brain Aβ burden and rescued cognitive deficits in the AD 
mouse model APP/PS1 (47). Although subsequent reports using bexarotene and LG100268, 
another RXR agonist, did not fully recapitulate these first findings with respect to plaque 
clearance, many of the beneficial effects have been reproduced in different studies (48, 49). 
RXR activation induces ApoE and ABCA1 expression, leading to an increase in ABCA1-
mediated lipidation of ApoE and high-density lipoprotein (HDL) levels in the brain. ApoE-
containing HDLs were shown to stimulate the proteolytic degradation of Aβ through 
microglial neprilysin and extracellular insulin-degrading enzyme (47, 50). It has been found 
that RXR activation by bexarotene induces Aβ phagocytosis by brain myeloid cells, which is 
associated with an increase in the expression of the phagocytic receptors MerTK, Axl, and 
Trem2 (51, 52). Bexarotene has also demonstrated direct neuroprotective effects in the AD 
mouse model 5xFAD, where it repressed inflammation, prevented neuronal loss, and was 
accompanied by an increase in synaptic markers and behavioral improvement (53). 
Although bexarotene has shown great therapeutic potential for AD in several animal models, 
its performance in clinical trials has been disappointing as it penetrates the blood-brain 
barrier poorly and elicits serious side effects, including hypertriglyceridemia (54). In a small 
clinical trial, however, AD patients with ApoE3 alleles experienced significant reduction in 
amyloid burden within 30 days of the start of treatment (55).
Moutinho et al. Page 5
Annu Rev Pharmacol Toxicol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2.2. RXR in Parkinson’s Disease
The available data indicate that there is adecrease in RXRα mRNA expression in the 
dopaminergic neurons of PD patients (Table 2). In 2013, a large screen of possible 
Nurr1/RXR ligands found that bexarotene preferentially bound to the Nurr1/RXR 
heterodimer. A low dose of bexarotene significantly protected dopamine neurons in the 
substantia nigra of the 6-hydroxydopamine (6OHDA) rat PD model, suggesting that low oral 
doses of bexarotene might provide an effective and well-tolerated therapy for PD (45). 
However, a different study reported conflicting results as bexarotene treatment failed to 
protect against dopaminergic cell loss, striatum innervation, and consequently motor 
impairment in PD animal models with 6-OHDA and α-syn overexpression (56). 
Nevertheless, bexarotene treatment did restore the expression of a subset of Nurr1 target 
genes, including GDNF and the receptor kinase Ret. Recently, it was shown that treatment of 
both α-syn overexpression and neurotoxin-lesioned PD mice models with BRF110, a 
synthetic molecule that is able to activate Nurr1 specifically through RXRα, exerted 
neuroprotective effects (57). Similarly, IRX4204, another synthetic drug that activates Nurr1 
through RXR binding, prevented a PD-like phenotype at the molecular, cellular, and 
behavioral levels in the 6- OHDA rat model (58). These reports support the potential value 
in exploring Nurr1:RXRα activation as a therapeutic approach for PD.
2.3. RXR in Huntington’s Disease
RXR isoform expression seems to be differentially regulated in the frontal cortex and 
caudate of HD patients, although an increase in RXRα is the most consistent change in these 
brain regions (Table 2). Recently, the RXR agonist bexarotene was shown to be 
neuroprotective when administered to the HD mouse model N171–82Q, rescuing the HD 
neurological phenotype and significantly extending the survival of these animals (59). Since 
RXR agonists are able to dimerize with different NRs, the authors proposed that bexarotene 
exerts its salutary effects by inducing the formation of an RXR:PPARβ/δ heterodimer. This 
heterodimer activates a specific genetic program that subsequently restores altered neuronal 
mitochondrial function and protein quality control in HD, leading to neuroprotection. 
Although a PPARβ/δ-specific ligand elicited a similar range of neuroprotective effects (60), 
it is important to note that RXR activation by bexarotene leads to the activation of several 
different genetic programs regulated by distinct NRs; hence, it is likely that PPARβ/δ is not 
the only receptor playing a role in this bexarotene effect.
2.4. RXR in Amyotrophic Lateral Sclerosis
Among the RXR isoforms there is a selective decrease of RXRγ mRNA levels in the spinal 
cords of ALS patients (Table 2). Treating the ALS mouse model SOD1G93A with the RXR 
agonist bexarotene attenuated the impaired motor function and weight loss, and increased 
survival by 30 % (61). The authors suggested that bexarotene exerted a neuroprotective 
effect on motor neurons by preserving synapses and reducing reactive astrogliosis. Given the 
limited therapeutic options for ALS, a clinical trial of bexarotene might be warranted.
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2.5. RAR in Alzheimer’s Disease
Increased RARα expression in the cortex of AD patients, possibly in both neuronal and 
nonneuronal cells depending on the specific cortical area (Table 2), could indicate important 
cell type–specific roles for this isoform in AD. The activation of this specific isoform, but 
not the others, is able to repress the production of Aβ (61) while simultaneously inducing 
microglial-mediated Aβ clearance (62), further suggesting an important role for RARα in 
AD pathology. As previously mentioned, vitamin A (retinol) metabolites, such as RA and 9-
cis-retinoic acid, are important endogenous agonists for RAR and RXR (23–25). Vitamin A 
deficiency has been correlated with cognitive decline in the elderly (63), and numerous 
studies have found lower levels of vitamin A in AD patients (Table 2). Both vitamin A 
deficiency and marginal vitamin A deficiency have been suggested to facilitate AD 
pathogenesis by increasing Aβ levels and deposition (63, 64) , which is consistent with the 
observation that RXR and RARs modulate both Aβ clearance and production in AD animal 
models (49).
It has been postulated that AD pathology is linked to the lack of availability of RA in the 
brain, which results in a feedback activation of retinaldehyde dehydrogenase (raldh), an 
enzyme involved in RA synthesis from vitamin A (65). Low levels of RA could be due to 
vitamin A deficiency in AD (Table 2), but it has also been observed that Aβ is able to 
repress RA synthesis (62), which suggests that there are pathological mechanisms that could 
be responsible for decreasing RA availability in the AD brain even in the presence of normal 
levels of vitamin A. Overall, RA deficiency and the subsequent impairment of RAR 
signaling might be important mechanisms in AD pathogenesis or disease progression. 
Unfortunately, adverse side effects and cytotoxicity of RA at higher concentrations have 
restricted its clinical applications. Tamibarotene ( Am80), a synthetic retinoid approved in 
Japan for the treatment of acute promyelocytic leukemia, is a RAR agonist with high 
specificity for RARα and RARβ. Treatment of APP23 transgenic mice with Am80 lowered 
insoluble Aβ40 and Aβ42 levels by upregulating expression of α-secretase (66), and in 
combination with HX630, an RXR agonist, Am80 drastically enhanced the learning ability 
of these mice (67). Am80 has been tested in patients suffering from AD in a small phase II 
clinical trial (68), but the results have not yet been disclosed. Acitretin, another RAR 
agonist, has also been tested in a pilot phase II clinical trial for AD (69). This study 
demonstrated the safety and tolerability of acitretin in human patients, and also reported that 
this drug promotes the nonamyloidogenic processing pathway of APP. In light of these 
results, the authors suggest that acitretin has promising therapeutic potential and should be 
tested in larger and longer trials. This is an uncommon case of a clinical trial using an NR-
targeted therapy that yielded promising results for a neurodegenerative disease, which 
warrants further clinical testing.
2.6. RAR in Parkinson’s Disease
Global gene expression analysis indicates that RARγ mRNA is increased in the striatum of 
PD patients (Table 2). There are no differences in serum levels of vitamin A in PD patients 
compared to controls (Table 2). It has been reported, however, that the transcript levels of 
raldh1 are markedly lower in the niagral neurons of PD patients, and that low levels of this 
enzyme in dopaminergic neurons correlate with neuronal dysfunction (68). This suggests 
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that reduced production of RA and retinoid signaling might be involved in PD pathogenesis; 
however, the study of RAR as a therapeutic target for PD has been very limited. The 
administration of RA-loaded polymeric nanoparticles to MPTP mice has a neuroprotective 
effect on dopaminergic neurons (70) , and the treatment of 6-OHDA mice with 9-cis-retinoic 
acid, which binds RAR even though it is an agonist of RXR, leads to neuroprotection of 
nigrostriatal dopaminergic neurons (71). Moreover, the RAR agonist Am80 prevents 
dopaminergic cell loss in the substantia nigra in mice challenged with lipopolysaccharide 
(72), which further suggests a potential neuroprotective role of RAR in diseases such as PD.
2.7. RAR in Huntington’s Disease
RARβ seems to be the only RAR isoform that exhibits abnormal expression in the brain of 
HD patients, as evidenced by reduced mRNA levels in the caudate (Table 2). Notably, the 
raldh1a1 transcript level is increased in the caudate of HD patients (73). Although vitamin A 
levels in HD patients have not been reported, one could speculate that this increase in 
raldh1a1 might be a compensatory mechanism for reduced vitamin A levels, analogous to 
what occurs in AD. The potential therapeutic role of RAR activation has not been explored 
in HD; however, it was recently reported that RARβ target genes are particularly affected in 
HD, which is thought to be due to sequestration of RARβ in htt protein aggregates (74). 
Hence, RARβ activation could be therapeutically relevant in HD.
2.8. RAR in Amyotrophic Lateral Sclerosis
RARα and RARγ transcript levels are downregulated in spinal cord motor neurons from 
ALS patients (Table 2). Conversely, the nuclear levels of RARβ are reported to be increased 
in motor neurons of sporadic ALS patients, suggesting higher activity (Table 2), which is 
proposed to be neuroprotective since increased RARβ activity is antiapoptotic and protects 
motor neurons from oxidative-induced cell death (75). It has been hypothesized that a defect 
in retinoid signaling could be a key factor in ALS pathogenesis. In spinal cord motor 
neurons from ALS patients, the expression of Raldh2, an enzyme that produces RA, is 
decreased (76), which suggests that there might be a depletion of retinoid ligands in spite of 
no changes in vitamin A levels, similar to what has been reported in PD (Table 2). The 
subsequent reduction in retinoid signaling could play an important role in disease 
progression. These data suggest that RARs could be a potential therapeutic target for ALS; 
however, the administration of RA to the ALS mouse model SOD1G93A was found to 
decrease the life span of the animals, although this effect was not due to an exacerbation of 
the pathology (77). In a small pilot trial, the treatment of ALS patients with RA and 
pioglitazone as an add-on to the traditional riluzole therapy did not delay disease progression 
(78).Nonetheless, the limitations of this study confound interpretation of the data, 
specifically the relatively small size of the trial, in which a significant number of patients 
discontinued RA due to their inability to tolerate its side effects, and the fact that all subjects 
started with a three-drug regimen.
2.9. LXR in Alzheimer’s Disease
Since LXR expression is not greatly affected in AD (Table 2), the availability of endogenous 
ligands might be a crucial factor that dictates LXR activity. A recent study reported that the 
levels of several oxysterols, including well-characterized LXR agonists, exhibit an abnormal 
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profile in the brain of late-stage AD patients (Table 2). Specifically, 27-hydroxycholesterol 
(27 OHC ) and 25-hydroxycholesterol (25OHC) levels were found to be increased and the 
levels of 24Shydroxycholesterol (24OHC) decreased. Moreover, desmosterol, another 
endogenous ligand of LXR, is also decreased in the AD brain (Table 2). Hence, it is not clear 
if the overall balance between the levels of LXR agonists in the AD brain would result in 
increased or reduced LXR activation. It is important to consider that desmosterol inhibits 
inflammatory gene expression, in part, through LXR-dependent mechanisms (79). A 
decrease in the LXR-mediated anti-inflammatory response in the AD brain due to reduced 
levels of desmosterol could be a relevant mechanism in AD pathogenesis or progression. 
Many studies have reported beneficial effects of different LXR ligands, with several animal 
models of AD showing a decreased Aβ burden and improved cognitive function. The 
underlying mechanisms are diverse, including modulation of neuronal function, Aβ 
degradation, anti-inflammatory mechanisms (3, 49), and the restoration of microvasculature 
architecture, which decreases Aβ deposition in blood vessels (80). It is still not clear to what 
extent the therapeutic roles of LXRα and LXRβ isoforms differ in neurodegenerative 
diseases; however, the development and utilization of isoform-selective agonists could shed 
some light on that subject. Since LXRβ activation, in contrast to LXRα, does not seem to 
induce hepatic steatosis, the side effects generally associated with LXR agonists could also 
be addressed by the use of isoform selective ligands (81).
2.10. LXR in Parkinson’s Disease
Similar to AD, both LXRα and LXRβ transcript levels do not seem to change in the striatum 
and substantia nigra of the brains of PD patients (Table 2). The plasma levels of 24OHC and 
27 OHC are similar in PD patients and controls, but 10% of a cohort of PD patients 
exhibited an increase in both of these oxysterols in the CSF (Table 2). The levels of 27OHC 
are particularly relevant in PD since it has been reported that 27OHC increases the levels of 
α-syn in human neuroblastoma cell lines through LXRβ, suggesting a deleterious effect on 
dopaminergic neurons in PD (82–84). On the other hand, the synthetic LXR agonist 
GW3965 exerts a neuroprotective effect in the MPTP PD mouse model by reducing the glial 
inflammatory response (85). Nonetheless, the role of LXRβ in an acute insult model, such as 
MPTP-lesioned mice, may greatly differ from its role in the context of a chronic progressive 
pathology.
2.11. LXR in Huntington’s Disease
In HD patients, transcriptomic analysis reveals that LXRα expression is increased in the 
caudate and LXRβ expression is decreased in the cerebellum (Table 2). It has been reported 
that wild-type htt acts as an LXR cofactor and that mhtt loses this function, thereby reducing 
the transcriptional activity of LXR and the expression of its target genes (86). Additionally, 
mhtt reduces ApoE secretion and cholesterol transport from astrocytes to neurons, leading to 
neuronal dysfunction, due to reduced expression of the LXR targets ABCA1 and Apo 
Einastrocytes(87,88).HD patients exhibit reduced levels of 24OHC in the putamen and 
caudate, while 27OHC and desmosterol are increased in the caudate (Table 2). Although the 
expression profile of LXR isoforms is not consistent across HD brain regions, the decrease 
in 24OHC is consistent with repression of the LXR pathway in glial cells, since 24OHC has 
been proposed to be an important regulator of the cholesterol shuttle from astrocytes to 
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neurons (89). This reduction of 24OHC is also observed in the CSF of several HD mouse 
models (87). The lack of LXR signaling, due to the interaction of this receptor with mhtt, 
and reduced levels of the LXR ligand 24OHC are likely to reduce cholesterol transport to 
neurons, which will very likely affect neuronal function and disease progression. Treatment 
of the R6/2 murine model of HD with cholesterol-loaded nanoparticles rescued synaptic 
dysfunction and cognitive deficits (90), which could be due to a compensation for the lack of 
LXR-mediated cholesterol transport. The treatment of R6/2 brain slices with the LXR 
agonist T0901317 reversed the abnormal electrophysiological profile observed in these mice 
(91). The same compound is able to partially rescue the phenotype of zebrafish lacking 
huntingtin (86). These studies suggest that LXR activation might be a promising therapeutic 
approach for HD.
2.12. LXR in Amyotrophic Lateral Sclerosis
Global gene expression analysis of motor neurons obtained from the spinal cord of sporadic 
ALS and control patients suggests that neuronal LXR expression does not change in ALS 
(Table 2). Hence, the levels of endogenous ligands may strongly dictate the activation status 
of these NRs. Although the CSF levels of desmosterol seem to be elevated in ALS patients 
compared to control samples, it is not clear how the levels of 24OHC and 27OHC change 
(Table 2). The CSF and serum levels of 25OHC are increased in ALS patients (Table 2), and 
serum levels of 25OHC are positively correlated with disease severity and progression (92). 
Based on in vitro results, these authors suggested that 25OHC is implicated in ALS 
progression by eliciting neurotoxic effects through activation of LXR in neurons. Although 
activation of LXR seems deleterious in this context, the lack of LXRβ in mice leads to the 
adult onset of an ALS-like motor neuron pathology (93). This apparent discrepancy might be 
related to the signaling of LXR in different cell types or even to the differences in signaling 
between LXR isoforms.
2.13. PPARs in Alzheimer’s Disease
The analysis of several transcriptomic data sets suggests that the expression of the PPAR 
isoforms remains unchanged in the brain of AD patients compared to controls (Table 2). 
However, a comparison between AD patients in different Braak stages revealed decreased 
mRNA expression of PPARα and PPARβ/δ and increased PPARγ expression in the brain 
throughout AD progression (94). The levels of several PUFA PPAR ligands, including DHA, 
are increased or decreased depending on the brain region (Table 2). Some of these changes 
in PUFA levels exhibit a significant correlation with disease progression in terms of 
neurofibrillar pathology, amyloid plaque burden, and cognitive decline (95). Furthermore, 
DHA and DHA-derived metabolites are able to specifically activate PPARγ, which leads to 
an inhibited inflammatory response and reduced Aβ production in animal models of AD (96, 
97); in light of these findings, it has been suggested that dietary intake of DHA could reduce 
the risk of AD (98). Several epidemiological studies have reported that treatment with 
nonsteroidal anti-inflammatory drugs reduces the risk of AD, possibly due to their ability to 
activate PPARγ (99), and the treatment of diabetic patients with the 
PPARγagonistpioglitazonereducestheriskofdementiaby47%(100).Thesefindingssupportthe 
idea that compromised PPARγ signaling might be involved in AD pathogenesis. The 
increase in PPARγ expression as AD progresses might result from a feedback mechanism 
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that boosts PPARγ signaling and controls inflammation. PPAR ligands seem to be beneficial 
in several experimental animal models of AD. Treatment of AD mouse models with pan-
PPAR agonists or agonists for specific PPARs isoforms leads to a decrease in Aβ burden, p-
tau, and inflammation, accompanied by an overall improvement of behavioral outcomes. 
The mechanisms underlying these PPAR effects seem to be related to Aβ production and 
clearance, neuronal function, anti-inflammatory mechanisms, and mitochondrial function 
(49, 101). The PPARγ agonist pioglitazone was recently described as being effective in 
reversing the Aβ-induced blood-brain barrier dysfunction in APP mice, rescuing the 
expression of several proteins involved in a variety of functions, including cerebrovascular 
vasocontractile tone and vascular compliance (102). A phase III study of pioglitazone, 
initiated by Takeda and Zinfandel Pharmaceuticals, is currently underway and is estimated to 
be completed in 2019. However, rosiglitazone, another PPARγ agonist, has shown no 
clinical efficacy in three phase III trials (103, 104).
2.14. PPARs in Parkinson’s Disease
ThemRNAexpressionofallPPARisoformsdoesnotseemtochangeinthestriatumandsubstantia 
nigra of PD patients compared to controls (Table 2). A significant decrease in the levels of 
several PUFA PPAR ligands has been reported in the anterior cingulate cortex, a region that 
shows accumulation of α-syn in PD (Table 2). In the occipital cortex, a region largely devoid 
of pathology, the levels of PUFAs are similar between PD and control samples (Table 2), 
suggesting that the changes in PUFAs are likely related to the pathophysiology of PD. 
Interestingly, in vitro evidence indicates that α-syn decreases PPARγ expression and 
signaling, which can be rescued by overexpressing PPARs or RXRα (105). A retrospective 
cohort study revealed that diabetic patients who were prescribed the PPARγ agonists 
rosiglitazone or pioglitazone exhibited a reduced risk of PD onset (106). These findings 
support the idea that inactivation of PPAR signaling in PD, specifically PPARγ, due to the 
lack of endogenous ligands and/or interaction with α-syn possibly contributes to PD 
pathogenesis and progression. Several studies have shown that various PPAR isoform 
agonists are neuroprotective in animal models of PD (107–111). Recently, pioglitazone was 
shown to exert its neuroprotective effects by facilitating hippocampal neurogenesis in 
6OHDA-lesioned rats (112). Rosiglitazone was also found to be neuroprotective in PD 
animal models, primarily by rescuing mitochondrial function and inducing the expression of 
antioxidative enzymes (107, 113). Despite the promising preclinical data and a good 
pharmacological profile, clinical trials using PPAR agonists have failed. A recent clinical 
trial concluded that pioglitazone is unlikely to be an effective intervention to slow disease 
progression in early PD and recommends that it should not be considered for further study 
(114).
2.15. PPARs in Huntington’s Disease
In HD patients, the pattern of PPAR expression is isoform and region specific, and plasma 
levels of fatty acids remain unaltered relative to controls (Table 2). Recently, it has been 
shown that mhtt interacts not only with LXR but also with the PPARβ/δ isoform and 
represses transactivation (60). Although PPARβ/δ expression levels do not change in the 
brains of patients (Table 2), the PPARβ/δ pathway is likely to be inhibited in the HD brain, 
especially in areas that accumulate mhtt. Treatment of the HD mouse model R6/2 with the 
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pan-PPAR agonist benzafibrate served a neuroprotective function, reduced HD 
neuropathologic features, and increased mitochondrial density in the striatum of these 
animals (115). Furthermore, the treatment of R6/2 mice with the PPARγ agonist 
rosiglitazone reversed motor deficits and weight loss and reduced htt aggregates, although 
there was only a modest increase in survival (116). The activation of PPARγ with 
rosiglitazone in the HD mouse model N171–82Q significantly improved motor function 
(117). The mechanisms underlying this protective effect of PPARγ in HD seem to be related 
to rescuing compromised mitochondrial function in HD, an increase in mechanisms that 
protect from oxidative stress, and preventing BDNF depletion (117, 118). Treatment of the 
HD mouse models BAC-HD97 and N171–82Q with the PPARβ/δ agonist KD3010 rescued 
the HD neurological phenotype, conferred neuroprotection, and extended survival (60). The 
underlying mechanism for the beneficial effects of PPARβ/δ in HD animal models, similar 
to PPARγ, seems to involve the rescuing of neuronal mitochondrial function. These 
preclinical results are very promising and support the idea of using this therapeutic strategy 
in future clinical trials for HD.
2.16. PPARs in Amyotrophic Lateral Sclerosis
In motor neurons obtained from the spinal cords of ALS patients, the transcript levels of 
PPAR isoforms do not change when compared to controls (Table 2). Nonetheless, DHA 
levels in the spinal cords of ALS patients are reduced (Table 2). The dietary intake of 
PUFAs, including DHA, has been correlated with a decreased risk or delayed onset of ALS 
(119, 120). In light of these findings, one could hypothesize that a reduction in PPAR 
activation in the spinal cord motor neurons of ALS, due to lack of endogenous ligands, could 
contribute to disease pathogenesis or progression. Treatment of the ALS mouse model 
SOD1G93A with the PPARγ agonist pioglitazone was neuroprotective and led to a decrease 
in inflammation, improved motor behavior, and extended survival (121, 122). In a recent 
screening of 1,200 US Food and Drug Administration–approved compounds, pioglitazone 
was identified as a neuroprotective agent in Drosophila ALS models. The treatment of the 
TDP-43 Drosophila ALS model with pioglitazone attenuated neuronal loss and mitigated 
motor dysfunction, although there was no increase in life span (123). These authors also 
demonstrated that pioglitazone is neuroprotective in an FUS, but not a SOD1G93A, 
Drosophila model. One of the proposed mechanisms underlying the beneficial effects of 
PPARγ in ALS is related to its role in the defense against lipid peroxidation by inducing the 
expression of lipid detoxification enzymes, such as lipoprotein lipase and glutathione S-
transferase α−2 (124). Administration of fenofibrate, a pan-PPAR agonist to SOD1G93A 
mice, elicited a significant delay in disease onset and progression, as well as prolonged 
survival of treated mice (125). The authors proposed that the neuroprotective properties of 
fenofibrate are related to a reduction in neuroinflammation and the protection of 
mitochondrial integrity. These encouraging findings suggest that PPAR is a promising drug 
target in ALS. However, a clinical trial using pioglitazone as an add-on therapy to riluzole 
reported that pioglitazone has no beneficial effects on the survival of ALS patients (126). 
Another trial also showed that pioglitazone treatment failed to alter clinical disease 
progression over a 6-month period in patients taking riluzole and tretinoin (78).
Moutinho et al. Page 12
Annu Rev Pharmacol Toxicol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2.17. Nurr1 in Alzheimer’s Disease
Although mRNA levels of Nurr1 were reported to be elevated in neurons of specific brain 
regions in AD, there seems to be a decrease in Nurr1 protein expression, particularly in 
neurons affected by p-tau aggregates (Table 2), suggesting that there might be region- and 
cell type–specific regulation of Nurr1 expression in AD.
2.18. Nurr1 in Parkinson’s Disease
There is a decrease in Nurr1 protein expression that appears to be selective to the substantia 
nigra and specifically to niagral neurons that contain α-syn inclusions (127). This 
observation is in line with another study reporting that α-syn is able to reduce Nurr1 
expression in niagral dopaminergic neurons in rats (40). The activation of Nurr1 using 
ligands for RXR is a promising strategy for PD, and a different class of drugs that activate 
Nurr1 through physical interaction with its ligand binding domain has also shown 
neuroprotective properties in PD models. The antimalarial drugs amodiaquine and 
chloroquine interact with the Nurr1 ligand binding domain and stimulate its transcriptional 
activity. This activation leads to a Nurr1-mediated increase in transcriptional activation of 
dopaminergic-specific genes in neurons and the transrepression of neurotoxic 
proinflammatory gene expression in microglia. This dual mechanism was proposed to be 
responsible for the significant improvement in behavioral deficits in the 6-OHDA rat model 
of PD that was treated with amodiaquine (128).
3. CONCLUSIONS AND FUTURE PERSPECTIVES
3.1. Experimental Models and Design
An extensive body of evidence has established that NR activation exerts a beneficial effect in 
preclinical animal models of neurodegenerative diseases. However, as Section 2 highlights, 
the translation of this therapeutic strategy to the clinic has not yet been successful. One 
possible reason could be related to the fact that the current animal models do not truly 
recapitulate human biology and pathology in all its complexity. Furthermore, the stage of the 
disease in which the model animals are treated with NR agonists could also be a critical 
determinant. In many studies, the treatment of these animal models starts significantly 
before they exhibit neuronal loss and cognitive or motor deficits, which therefore does not 
correspond to the symptomatic stage of patients when starting medication. In essence, many 
of the treatment paradigms used in a vast number of animal studies are more analogous to a 
prevention strategy rather than a treatment strategy. This could contribute to the failure of 
translation into clinical practice, as the activation of particular NRs might only be effective 
at very early stages of disease, or merely as a prevention strategy, and not in patients with 
advanced symptomatic pathologies. This rationale could explain why the epidemiological 
studies demonstrating a reduced risk for neurodegenerative diseases in people taking PPAR 
agonists for other indications are in agreement with several studies using animal models, 
while later-stage clinical trials fail to demonstrate the efficacy of this type of drug. Overall, 
the different biology of animal models compared to humans is an unavoidable limitation that 
will account for translational limitations; however, the stage of disease progression at which 
researchers start treatment of these animals should be carefully determined, taking into 
account clinical practice in human patients. This might be a crucial detail in the study design 
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that could dictate the translational success of a particular therapeutic strategy. Another key 
factor to consider is the peripheral impact of NR agonists, especially with respect to adverse 
effects. This can be circumvented by designing selective agonists for particular NR isoforms, 
using targeted strategies for drug delivery, adjusting the dosage, or using combination 
therapies with drugs that mitigate the peripheral side effects. Taking these concerns into 
consideration when designing experiments in animal models will increase the chance of a 
successful translation to clinical trials.
3.2. Novel Research Avenues
The analysis of different experimental data sets and human studies suggests that each 
neurodegenerative disease exhibits its own distinct pattern of NR dysfunction. Indeed, the 
activation of some NRs, such as LXR, might be detrimental in particular diseases, such as 
PD or ALS (82–84 , 92), and beneficial in others. Hence, novel therapeutic strategies 
involving NRs might need to be specific for each disease. However, as highlighted in 
Sections 2.5–2.8, the gene expression analysis of human patients suggests that the repression 
of RA synthesis, which leads to a reduction of retinoid signaling through RAR, might be a 
common mechanism involved in the pathogenesis or disease progression of AD, PD, HD, 
and ALS (Figure 3). This idea is supported by several preclinical and a few clinical studies 
using synthetic agonists for RAR, highlighted in Sections 2.5 and 2.8. Although this latter 
strategy has already shown promising results in both preclinical and some clinical studies, it 
is a very targeted approach to RARs. Thus, it might not fully reestablish the endogenous 
roles of RA in the brain, such as the regulation of RARs activation patterns in specific cell 
types or brain regions that synthetic agonists may not be able to recapitulate and also other 
endogenous roles not directly related to NRs. An alternate strategy to address this retinoid 
deficit could be to restore the levels of RA synthesis in the affected areas by activating the 
synthesis pathway, which seems to be compromised in these diseases. The inhibition of RA 
catabolism by inhibiting the retinoic acid 4-hydroxylase (CYP26) could also be a promising 
approach (Figure 3). Additionally, this strategy would restore not only RAR signaling but 
also other NR pathways, including PPAR, Nurr1, and LXR. Indeed, RA has been shown to 
activate PPARβ/δ (129), maintain Nurr1 expression in a PD mouse model (130), and induce 
the LXR target gene ABCA1 in macrophages (131). Overall, the restoration of RA 
homeostasis might be a very promising therapeutic approach for several neurodegenerative 
diseases, as it seems to be a common feature across these disorders.
ACKNOWLEDGMENTS
This work was supported by a Weston Brain Institute Postdoctoral Fellowship Award from the W. Garfield Weston 
Foundation and an Eli Lilly–Stark Research Fellowship in neurodegeneration.
LITERATURE CITED
1. Wood LB, Winslow AR, Strasser SD. 2015 Systems biology of neurodegenerative diseases. Integr. 
Biol 7 :758–75
2. Saijo K, Crotti A, Glass CK. 2010 Nuclear receptors, inflammation, and neurodegenerative diseases. 
Adv. Immunol 106:21–59 [PubMed: 20728023] 
3. Skerrett R, Malm T, Landreth G. 2014 Nuclear receptors in neurodegenerative diseases. Neurobiol. 
Dis 72(Pt. A):104–16 [PubMed: 24874548] 
Moutinho et al. Page 14
Annu Rev Pharmacol Toxicol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4. Evans RM, Mangelsdorf DJ. 2014 Nuclear receptors, RXR, and the Big Bang. Cell 157:255–66 
[PubMed: 24679540] 
5. Musiek ES, Holtzman DM. 2015 Three dimensions of the amyloid hypothesis: time, space and 
‘wingmen’. Nat. Neurosci 18:800–6 [PubMed: 26007213] 
6. Chow VW, Mattson MP, Wong PC, Gleichmann M. 2010 An overview of APP processing enzymes 
and products. Neuromolecular Med 12:1–12 [PubMed: 20232515] 
7. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, et al. 2010 Decreased clearance of 
CNS β-amyloid in Alzheimer’s disease. Science 330:1774 [PubMed: 21148344] 
8. Klein C, Westenberger A. 2012 Genetics of Parkinson’s disease. Cold Spring Harb. Perspect. Med 
2:a008888 [PubMed: 22315721] 
9. Stefanis L. 2012 α-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med 2:a009399 
[PubMed: 22355802] 
10. Dauer W, Przedborski S. 2003 Parkinson’s disease: mechanisms and models. Neuron 39:889–909 
[PubMed: 12971891] 
11. Nolan YM, Sullivan AM, Toulouse A. 2013 Parkinson’s disease in the nuclear age of neuro 
inflammation. Trends Mol. Med 19:187–96 [PubMed: 23318001] 
12. Saudou F, Humbert S. 2016 The biology of Huntingtin. Neuron 89:910–26 [PubMed: 26938440] 
13. Landles C, Bates GP. 2004 Huntingtin and the molecular pathogenesis of Huntington’s disease. 
EMBO Rep 5:958–63 [PubMed: 15459747] 
14. Ajroud-Driss S, Siddique T. 2015 Sporadic and hereditary amyotrophic lateral sclerosis (ALS). 
Biochim. Biophys. Acta 1852:679–84 [PubMed: 25193032] 
15. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, et al. 2011 Amyotrophic lateral sclerosis. 
Lancet 377:942–55 [PubMed: 21296405] 
16. Sever R, Glass CK. 2013 Signaling by nuclear receptors. Cold Spring Harb. Perspect. Biol 
5:a016709 [PubMed: 23457262] 
17. Dawson MI, Xia Z. 2012 The retinoid X receptors and their ligands. Biochim. Biophys. Acta 
1821:21–56 [PubMed: 22020178] 
18. Lammi J, Perlmann T, Aarnisalo P. 2008 Corepressor interaction differentiates the permissive and 
non-permissive retinoid X receptor heterodimers. Arch. Biochem. Biophys 472:105–14 [PubMed: 
18282463] 
19. Glass CK, Saijo K. 2010 Nuclear receptor transrepression pathways that regulate inflammation in 
macrophages and T cells. Nat. Rev. Immunol 10:365–76 [PubMed: 20414208] 
20. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, et al. 2009 A Nurr1/CoREST pathway in 
microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 
137:47–59 [PubMed: 19345186] 
21. Krezel W, Kastner P, Chambon P. 1999 Differential expression of retinoid receptors in the adult 
mouse central nervous system. Neuroscience 89:1291–300 [PubMed: 10362315] 
22. Arfaoui A, Lobo MV, Boulbaroud S, Ouichou A, Mesfioui A, Arenas MI. 2013 Expression of 
retinoic acid receptors and retinoid X receptors in normal and vitamin A deficient adult rat brain. 
Ann. Anat 195:111–21 [PubMed: 23017197] 
23. Desvergne B. 2007 RXR: from partnership to leadership in metabolic regulations. Vitam. Horm 
75:1–32 [PubMed: 17368310] 
24. Ruhl R, Krzyzosiak A, Niewiadomska-Cimicka A, Rochel N, Szeles L, et al. 2015 9-
cis-13,14dihydroretinoic acid is an endogenous retinoid acting as RXR ligand in mice. PLOS 
Genet 11:e1005213 [PubMed: 26030625] 
25. Lane MA, Bailey SJ. 2005 Role of retinoid signaling in the adult brain. Prog. Neurobiol 75:275–93 
[PubMed: 15882777] 
26. Chiang MY, Misner D, Kempermann G, Schikorski T, Giguere V, et al. 1998 An essential role for 
retinoid receptors RARβand RXRγin long-term potentiation and depression. Neuron 21:1353–61 
[PubMed: 9883728] 
27. Sarti F, Schroeder J, Aoto J, Chen L. 2012 Conditional RARαknockout mice reveal acute 
requirement for retinoic acid and RARαin homeostatic plasticity. Front. Mol. Neurosci 5:16 
[PubMed: 22419906] 
Moutinho et al. Page 15
Annu Rev Pharmacol Toxicol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
28. Ransom J, Morgan PJ, McCaffery PJ, Stoney PN. 2014 The rhythm of retinoids in the brain. J. 
Neurochem 129:366–76 [PubMed: 24266881] 
29. Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, et al. 2002 Regulation of 
cholesterol homeostasis by the liver X receptors in the central nervous system. Mol. Endocrinol 
16:1378–85 [PubMed: 12040022] 
30. Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA. 2002 Liver X receptors 
in the central nervous system: from lipid homeostasis to neuronal degeneration. PNAS 99:13878–
83 [PubMed: 12368482] 
31. Andersson S, Gustafsson N, Warner M, Gustafsson JA. 2005 Inactivation of liver X receptor βleads 
to adult-onset motor neuron degeneration in male mice. PNAS 102:3857–62 [PubMed: 15738425] 
32. Warden A, Truitt J, Merriman M, Ponomareva O, Jameson K, et al. 2016 Localization of PPAR 
isotypes in the adult mouse and human brain. Sci. Rep 6:27618 [PubMed: 27283430] 
33. Wahli W, Michalik L. 2012 PPARs at the crossroads of lipid signaling and inflammation. Trends 
Endocrinol. Metab 23:351–63 [PubMed: 22704720] 
34. Kapadia R, Yi JH, Vemuganti R. 2008 Mechanisms of anti-inflammatory and neuroprotective 
actions of PPAR-γ agonists. Front. Biosci 13:1813–26 [PubMed: 17981670] 
35. Quintanilla RA, Utreras E, Cabezas-Opazo FA. 2014 Role of PPAR γin the differentiation and 
function of neurons. PPAR Res 2014:768594 [PubMed: 25246934] 
36. Fidaleo M, Fanelli F, Ceru MP, Moreno S. 2014Neuroprotective properties of peroxisome 
proliferator -activated receptor alpha (PPARα) and its lipid ligands. Curr. Med. Chem 21:2803–21 
[PubMed: 24606520] 
37. Chakravarthy MV, Zhu Y, Lopez M, Yin L, Wozniak DF, et al. 2007 Brain fatty acid synthase 
activates PPARαto maintain energy homeostasis. J. Clin. Investig 117:2539–52 [PubMed: 
17694178] 
38. Roy A, Jana M, Kundu M, Corbett GT, Rangaswamy SB, et al. 2015 HMG-CoA reductase 
inhibitors bind to PPARα to upregulate neurotrophin expression in the brain and improve memory 
in mice. Cell Metab 22:253–65 [PubMed: 26118928] 
39. Hall MG, Quignodon L, Desvergne B. 2008 Peroxisome proliferator-activated receptor β/δ in the 
brain: facts and hypothesis. PPAR Res 2008:780452 [PubMed: 19009042] 
40. Decressac M, Volakakis N, Bjorklund A, Perlmann T. 2013 NURR1 in Parkinson disease—from 
pathogenesis to therapeutic potential. Nat. Rev. Neurol 9:629–36 [PubMed: 24126627] 
41. Law SW, Conneely OM, DeMayo FJ, O’Malley BW. 1992 Identification of a new brain-specific 
transcription factor, NURR1. Mol. Endocrinol 6:2129–35 [PubMed: 1491694] 
42. Zetterstrom RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T. 1997 Dopamine neuron 
agenesis in Nurr1-deficient mice. Science 276:248–50 [PubMed: 9092472] 
43. Jiang C, Wan X, He Y, Pan T, Jankovic J, Le W. 2005 Age-dependent dopaminergic dysfunction in 
Nurr1 knockout mice. Exp. Neurol 191:154–62 [PubMed: 15589522] 
44. Kadkhodaei B, Ito T, Joodmardi E, Mattsson B, Rouillard C, et al. 2009 Nurr1 is required for 
maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci 29:15923–32 
[PubMed: 20016108] 
45. McFarland K, Spalding TA, Hubbard D, Ma JN, Olsson R, Burstein ES. 2013 Low dose bexarotene 
treatment rescues dopamine neurons and restores behavioral function in models of Parkinson’s 
disease. ACS Chem. Neurosci 4:1430–38 [PubMed: 24117438] 
46. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. 2010 Increased expression of RXRα in 
dementia: an early harbinger for the cholesterol dyshomeostasis? Mol. Neurodegener 5:36 
[PubMed: 20843353] 
47. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, et al. 2012 ApoE-directed therapeutics 
rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335:1503–6 [PubMed: 
22323736] 
48. Tesseur I, De Strooper B. 2013When the dustsettles: What did we learn from the bexarotene 
discussion? Alzheimers Res. Ther 5:54 [PubMed: 24229456] 
49. Moutinho M, Landreth GE. 2017 Therapeutic potential of nuclear receptor agonists in Alzheimer’s 
disease. J. Lipid Res 58:1937–49 [PubMed: 28264880] 
Moutinho et al. Page 16
Annu Rev Pharmacol Toxicol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
50. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, et al. 2008 ApoE promotes the proteolytic 
degradation of Aβ. Neuron 58:681–93 [PubMed: 18549781] 
51. Savage JC, Jay T, Goduni E, Quigley C, Mariani MM, et al. 2015Nuclear receptors license 
phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer’s disease. J. Neurosci 
35:6532–43 [PubMed: 25904803] 
52. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. 2012 PPARγ/RXRα- 
induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement 
in amyloid precursor protein/presenilin 1 mice. J. Neurosci 32:17321–31 [PubMed: 23197723] 
53. Mariani MM, Malm T, Lamb R, Jay TR, Neilson L, et al. 2017 Neuronally-directed effects of RXR 
activation in a mouse model of Alzheimer’s disease. Sci. Rep 7:42270 [PubMed: 28205585] 
54. Ghosal K, Haag M, Verghese PB, West T, Veenstra T, et al. 2016 A randomized controlled study to 
evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy 
subjects. Alzheimers Dement 2:110–20
55. Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, et al. 2016 Double-blind, 
placebocontrolled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease. 
Alzheimers Res. Ther 8:4 [PubMed: 26822146] 
56. Volakakis N, Tiklova K, Decressac M, Papathanou M, Mattsson B, et al. 2015 Nurr1 and retinoid X 
receptor ligands stimulate Ret signaling in dopamine neurons and can alleviate α-synuclein 
disrupted gene expression. J. Neurosci 35:14370–85 [PubMed: 26490873] 
57. Spathis AD, Asvos X, Ziavra D, Karampelas T, Topouzis S, et al. 2017 Nurr1:RXRα heterodimer 
activation as monotherapy for Parkinson’s disease. PNAS 114:3999–4004 [PubMed: 28348207] 
58. Wang J, Bi W, Zhao W, Varghese M, Koch RJ, et al. 2016 Selective brain penetrable Nurr1 
transactivator for treating Parkinson’s disease. Oncotarget 7:7469–79 [PubMed: 26862735] 
59. Dickey AS, Sanchez DN, Arreola M, Sampat KR, Fan W, et al. 2017 PPARδactivation by 
bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis. 
Sci. Transl. Med 9(419): eaal 2332
60. Dickey AS, Pineda VV, Tsunemi T, Liu PP, Miranda HC, et al. 2016 PPAR-δ is repressed in 
Huntington’s disease, is required for normal neuronal function and can be targeted therapeutically. 
Nat. Med 22:37–45 [PubMed: 26642438] 
61. Riancho J, Ruiz-Soto M, Berciano MT, Berciano J, Lafarga M. 2015 Neuroprotective effect of 
bexarotene in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Front. Cell. Neurosci 
9:250 [PubMed: 26190974] 
62. Goncalves MB, Clarke E, Hobbs C, Malmqvist T, Deacon R, et al. 2013 Amyloid βinhibits retinoic 
acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic 
acid receptor αagonist. Eur. J. Neurosci 37:1182–92 [PubMed: 23379615] 
63. Zeng J, Chen L, Wang Z, Chen Q, Fan Z, et al. 2017 Marginal vitamin A deficiency facilitates 
Alzheimer’s pathogenesis. Acta Neuropathol 133:967–82 [PubMed: 28130638] 
64. Reinhardt S, Grimm MO,Stahlmann C, Hartmann T, Shudo K,et al. 2016 .Rescue of 
hypovitaminosis A induces non-amyloidogenic amyloid precursor protein (APP) processing. Curr. 
Alzheimer Res 13:1277–89 [PubMed: 27335034] 
65. Goodman AB, Pardee AB. 2003 Evidence for defective retinoid transport and function in late onset 
Alzheimer’s disease. PNAS 100:2901–5 [PubMed: 12604774] 
66. Kawahara K, Nishi K, Suenobu M, Ohtsuka H, Maeda A, et al. 2009 Oral administration of 
synthetic retinoid Am80 (tamibarotene) decreases brain β-amyloid peptides in APP23 mice. Biol. 
Pharm. Bull 32:1307–9 [PubMed: 19571405] 
67. Kawahara K, Suenobu M, Ohtsuka H, Kuniyasu A, Sugimoto Y, et al. 2014 Cooperative 
therapeutic action of retinoic acid receptor and retinoid X receptor agonists in a mouse model of 
Alzheimer’s disease. J. Alzheimers Dis 42:587–605 [PubMed: 24916544] 
68. Fukasawa H, Nakagomi M, Yamagata N, Katsuki H, Kawahara K, et al. 2012 Tamibarotene: a 
candidate retinoid drug for Alzheimer’s disease. Biol. Pharm. Bull 35:1206–12 [PubMed: 
22863914] 
69. Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, et al. 2014 Increased CSF APPs-α levels in 
patients with Alzheimer disease treated with acitretin. Neurology 83:1930–35 [PubMed: 
25344383] 
Moutinho et al. Page 17
Annu Rev Pharmacol Toxicol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
70. Esteves M, Cristovao AC, Saraiva T, Rocha SM, Baltazar G, et al. 2015 Retinoic acid-loaded 
polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson’s disease. Front. 
Aging Neurosci 7:20 [PubMed: 25798108] 
71. Yin LH, Shen H, Diaz-Ruiz O, Backman CM, Bae E, et al. 2012 Early post-treatment with 9-cis 
retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson’s 
disease. BMC Neurosci 13:120 [PubMed: 23040108] 
72. Katsuki H, Kurimoto E, Takemori S, Kurauchi Y, Hisatsune A, et al. 2009 Retinoic acid receptor 
stimulation protects midbrain dopaminergic neurons from inflammatory degeneration via BDNF-
mediated signaling. J. Neurochem 110:707–18 [PubMed: 19457078] 
73. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, et al. 2006 Regional and cellular gene 
expression changes in human Huntington’s disease brain. Hum. Mol. Genet 15:965–77 [PubMed: 
16467349] 
74. Niewiadomska-Cimicka A, Krzyzosiak A, Ye T, Podlesny-Drabiniok A, Dembele D, et al. 2017 
Genome-wide analysis of RARβ transcriptional targets in mouse striatum links retinoic acid 
signaling with Huntington’s disease and other neurodegenerative disorders. Mol. Neurobiol 
54:3859–78 [PubMed: 27405468] 
75. Kolarcik CL, Bowser R. 2012 Retinoid signaling alterations in amyotrophic lateral sclerosis. Am. 
J. Neurodegener. Dis 1:130–45 [PubMed: 23383387] 
76. Corcoran J, So PL, Maden M. 2002 Absence of retinoids can induce motoneuron disease in the 
adult rat and a retinoid defect is present in motoneuron disease patients. J. Cell Sci 115:4735–41 
[PubMed: 12432062] 
77. Crochemore C, Virgili M, Bonamassa B, Canistro D, Pena-Altamira E, et al. 2009 Long-term 
dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of 
G93A mice, a model for amyotrophic lateral sclerosis. Muscle Nerve 39:548–52 [PubMed: 
19296491] 
78. Levine TD, Bowser R, Hank NC, Gately S, Stephan D, et al. 2012 A pilot trial of pioglitazone HCl 
and tretinoin in ALS: cerebrospinal fluid biomarkers to monitor drug efficacy and predict rate of 
disease progression. Neurol. Res. Int 2012:582075 [PubMed: 22830016] 
79. Spann NJ, Garmire LX, McDonald JG, Myers DS, Milne SB, et al. 2012 Regulated accumulation 
of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell 
151:138–52 [PubMed: 23021221] 
80. Sandoval-Hernandez AG, Restrepo A, Cardona-Gomez GP, Arboleda G. 2016 LXR activation 
protects hippocampal microvasculature in very oldtriple transgenic mouse model of Alzheimer’s 
disease. Neurosci. Lett 621:15–21 [PubMed: 27057732] 
81. Lee JH, Park SM, Kim OS, Lee CS, Woo JH, et al. 2009 Differential SUMO ylation of LXRα and 
LXRβ mediates transrepression of STAT1 inflammatory signaling in IFN-γ-stimulated brain 
astrocytes. Mol. Cell 35:806–17 [PubMed: 19782030] 
82. Cheng D, Kim WS, Garner B. 2008 Regulation of α-synuclein expression by liver X receptor 
ligands in vitro. Neuroreport 19:1685–89 [PubMed: 18841091] 
83. Marwarha G, Rhen T, Schommer T, Ghribi O. 2011 The oxysterol 27-hydroxycholesterol regulates 
α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through 
modulation of liver X receptors and estrogen receptors—relevance to Parkinson’s disease. J. 
Neurochem 119:1119–36 [PubMed: 21951066] 
84. Rantham Prabhakara JP, Feist G, Thomasson S, Thompson A, Schommer E, Ghribi O. 2008 
Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase 
and α-synuclein in human neuroblastoma SH-SY5Y cells. J. Neurochem 107:1722–29 [PubMed: 
19014385] 
85. Dai YB, Tan XJ, Wu WF, Warner M, Gustafsson JA. 2012 Liver X receptor βprotects 
dopaminergic neurons in a mouse model of Parkinson disease. PNAS 109:13112–17 [PubMed: 
22826221] 
86. Futter M, Diekmann H, Schoenmakers E, Sadiq O, Chatterjee K, Rubinsztein DC. 2009 Wild-type 
but not mutant huntingtin modulates the transcriptional activity of liver X receptors. J. Med. Genet 
46:438–46 [PubMed: 19451134] 
Moutinho et al. Page 18
Annu Rev Pharmacol Toxicol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
87. Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, et al. 2010 Cholesterol defect is marked 
across multiple rodent models of Huntington’s disease and is manifest in astrocytes. J. Neurosci 
30:10844–50 [PubMed: 20702713] 
88. Valenza M, Marullo M, Di Paolo E, Cesana E, Zuccato C, et al. 2015 Disruption of astrocyte-
neuron cholesterol cross talk affects neuronal function in Huntington’s disease. Cell Death Differ 
22:690–702 [PubMed: 25301063] 
89. Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AH, et al. 2006 
24(S)hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that 
regulates apolipoprotein E-mediated cholesterol efflux. J. Biol. Chem 281:12799–808 [PubMed: 
16524875] 
90. Valenza M, Chen JY, Di Paolo E, Ruozi B, Belletti D, et al. 2015 Cholesterol-loaded nanoparticles 
ameliorate synaptic and cognitive function in Huntington’s disease mice. EMBO Mol. Med 
7:1547–64 [PubMed: 26589247] 
91. Chen JY, Tran C, Hwang L, Deng G, Jung ME, et al. 2016 Partial amelioration of peripheral and 
central symptoms of Huntington’s disease via modulation of lipid metabolism. J. Huntingtons Dis 
5:65–81 [PubMed: 27031732] 
92. Kim SM, Noh MY, Kim H, Cheon SY, Lee KM, et al. 2017 25-Hydroxycholesterol is involved in 
the pathogenesis of amyotrophic lateral sclerosis. Oncotarget 8:11855–67 [PubMed: 28060747] 
93. Bigini P,Steffensen KR,Ferrario A,Diomede L,Ferrara G,et al.
2010Neuropathologicandbiochemical changes during disease progression in liver X receptor β−/− 
mice, a model of adult neuron disease. J. Neuropathol. Exp. Neurol 69:593–605 [PubMed: 
20467332] 
94. de la Monte SM, Wands JR. 2006 Molecular indices of oxidative stress and mitochondrial 
dysfunction occur early and often progress with severity of Alzheimer’s disease. J. Alzheimer’s 
Dis 9:167–81 [PubMed: 16873964] 
95. Snowden SG, Ebshiana AA, Hye A, An Y, Pletnikova O, et al. 2017 Association between fatty acid 
metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: 
anontargeted metabolomic study. PLOS Med 14:e1002266 [PubMed: 28323825] 
96. Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, et al. 2011 Docosahexaenoic acid-derived 
neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in 
Alzheimer’s disease models. PLOS ONE 6:e15816 [PubMed: 21246057] 
97. Lim GP, Calon F, Morihara T, Yang F, Teter B, et al. 2005 A diet enriched with the omega-3 fatty 
acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. 
Neurosci 25:3032–40 [PubMed: 15788759] 
98. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, et al. 2003 Consumption of fish and 
n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol 60:940–46 [PubMed: 
12873849] 
99. Kummer MP, Heneka MT. 2008 PPARs in Alzheimer’s disease. PPAR Res 2008:403896 [PubMed: 
18645613] 
100. Heneka MT, Fink A, Doblhammer G. 2015 Effect of pioglitazone medication on the incidence of 
dementia. Ann. Neurol 78:284–94 [PubMed: 25974006] 
101. Heneka MT, Reyes-Irisarri E, Hull M, Kummer MP. 2011 Impact and therapeutic potential of 
PPARs in Alzheimer’s disease. Curr. Neuropharmacol 9:643–50 [PubMed: 22654722] 
102. Badhwar A, Brown R, Stanimirovic DB, Haqqani AS, Hamel E. 2017 Proteomic differences in 
brain vessels of Alzheimer’s disease mice: normalization by PPARγ agonist pioglitazone. J. 
Cereb. Blood Flow Metab 37:1120–36 [PubMed: 27339263] 
103. Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, et al. 2011 Rosiglitazone does not 
improve cognition or global function when used as adjunctive therapy to AChE inhibitors in 
mild-to-moderate Alzheimer’s disease: two phase 3 studies. Curr. Alzheimer Res 8:592–606 
[PubMed: 21592048] 
104. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, et al. 2010 Rosiglitazone 
monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, 
placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord 30:131–46 [PubMed: 
20733306] 
Moutinho et al. Page 19
Annu Rev Pharmacol Toxicol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
105. Yakunin E, Kisos H, Kulik W, Grigoletto J, Wanders RJ, Sharon R. 2014 The regulation of 
catalase activity by PPAR γis affected by α-synuclein. Ann. Clin. Transl. Neurol 1:145–59 
[PubMed: 25356396] 
106. Brauer R, Bhaskaran K, Chaturvedi N, Dexter DT, Smeeth L, Douglas I. 2015 Glitazone 
treatment and incidence of Parkinson’s disease among people with diabetes: a retrospective 
cohort study. PLOS Med 12:e1001854 [PubMed: 26196151] 
107. Corona JC, Duchen MR. 2015 PPARγand PGC-1αas therapeutic targets in Parkinson’s. 
Neurochem. Res 40:308–16 [PubMed: 25007880] 
108. Carta AR. 2013 PPAR-γ: therapeutic prospects in Parkinson’s disease. Curr. Drug Targets 
14:743–51 [PubMed: 23469878] 
109. Barbiero JK, Santiago RM, Persike DS, da Silva Fernandes MJ, Tonin FS, et al. 2014 
Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists 
in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. 
Behav. Brain Res 274:390–99 [PubMed: 25127682] 
110. Martin HL, Mounsey RB, Sathe K, Mustafa S, Nelson MC, et al. 2013 A peroxisome proliferator-
activated receptor-δ agonist provides neuroprotection in the 1methyl-4-
phenyl-1,2,3,6tetrahydropyridine model of Parkinson’s disease. Neuroscience 240:191–203 
[PubMed: 23500098] 
111. Chaturvedi RK,Beal MF. 2008 PPAR:atherapeutictargetinParkinson’sdisease. 
J.Neurochem106:506–18 [PubMed: 18384649] 
112. Bonato JM, Bassani TB, Milani H, Vital M, de Oliveira RMW. 2018 Pioglitazone reduces 
mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-
OHDA model of Parkinson’s disease in rats. Exp. Neurol 300:188–200 [PubMed: 29162435] 
113. Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, et al. 2007Rosiglitazone protects human 
neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of 
mitochondrial dysfunction and ROS production. J. Neurol. Sci 253:53–60 [PubMed: 17266988] 
114. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. 2015 
Pioglitazone in early Parkinson’s disease: a phase 2, multicentre, double-blind, randomised trial. 
Lancet. Neurol 14:795–803 [PubMed: 26116315] 
115. Johri A, Calingasan NY, Hennessey TM, Sharma A, Yang L, et al. 2012 Pharmacologic activation 
of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of 
Huntington’s disease. Hum. Mol. Genet 21:1124–37 [PubMed: 22095692] 
116. Chiang MC, Chen CM, Lee MR, Chen HW, Chen HM, et al. 2010 Modulation of energy 
deficiency in Huntington’s disease via activation of the peroxisome proliferator-activated 
receptor γ. Hum. Mol. Genet 19:4043–58 [PubMed: 20668093] 
117. Jin J, Albertz J, Guo Z, Peng Q, Rudow G, et al. 2013 Neuroprotective effects of PPAR-γ agonist 
rosiglitazone in N171–82Q mouse model of Huntington’s disease. J. Neurochem 125:410–19 
[PubMed: 23373812] 
118. Chiang MC, Chern Y, Huang RN. 2012 PPARγrescue of the mitochondrial dysfunction in 
Huntington’s disease. Neurobiol. Dis 45:322–28 [PubMed: 21907283] 
119. Veldink JH, Kalmijn S, Groeneveld GJ, Wunderink W, Koster A, et al. 2007 Intake of 
polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral 
sclerosis. J. Neurol. Neurosurg. Psychiatry 78:367–71 [PubMed: 16648143] 
120. Fitzgerald KC, O’Reilly EJ, Falcone GJ, McCullough ML, Park Y, et al. 2014 Dietary ω−3 
polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol 
71:1102–10 [PubMed: 25023276] 
121. Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. 2005 Peroxisome proliferator-activated 
receptorγ agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. 
Exp. Neurol 191:331–36 [PubMed: 15649489] 
122. Schutz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, et al. 2005 The oral 
an tidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like 
symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci 25:7805–12 [PubMed: 
16120782] 
Moutinho et al. Page 20
Annu Rev Pharmacol Toxicol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
123. Joardar A, Menzl J, Podolsky TC, Manzo E, Estes PS, et al. 2015 PPAR gamma activation is 
neuroprotective in a Drosophila model of ALS based on TDP-43. Hum. Mol. Genet 24:1741–54 
[PubMed: 25432537] 
124. Benedusi V, Martorana F, Brambilla L, Maggi A, Rossi D. 2012 The peroxisome proliferator-
activated receptor γ (PPARγ) controls natural protective mechanisms against lipid peroxidation 
in amyotrophic lateral sclerosis. J. Biol. Chem 287:35899–911 [PubMed: 22910911] 
125. Esmaeili MA, Yadav S, Gupta RK, Waggoner GR, Deloach A, et al. 2016 Preferential PPAR-α 
activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Hum. Mol. Genet 
25:317–27 [PubMed: 26604138] 
126. Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, et al. 2012 A randomized, double blind, 
placebocontrolled trial of pioglitazone in combination with riluzole in amyotrophic lateral 
sclerosis. PLOS ONE 7:e37885 [PubMed: 22715372] 
127. Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. 2006 Nurr1 in Parkinson’s 
disease and related disorders. J. Comp. Neurol 494:495–514 [PubMed: 16320253] 
128. Kim CH, Han BS, Moon J, Kim DJ, Shin J, et al. 2015 Nuclear receptor Nurr1 agonists enhance 
its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease. 
PNAS 112:8756–61 [PubMed: 26124091] 
129. Shaw N, Elholm M, Noy N. 2003 Retinoic acid is a high affinity selective ligand for the 
peroxisome proliferator-activated receptor β/δ. J. Biol. Chem 278:41589–92 [PubMed: 
12963727] 
130. Dong J, Li S, Mo JL, Cai HB, Le WD. 2016 Nurr1-based therapies for Parkinson’s disease. CNS 
Neurosci. Ther 22:351–59 [PubMed: 27012974] 
131. Costet P, Lalanne F, Gerbod-Giannone MC, Molina JR, Fu X, et al. 2003 Retinoic acid 
receptormediated induction of ABCA1 in macrophages. Mol. Cell. Biol 23:7756–66 [PubMed: 
14560020] 
132. Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F. 2009 Up-regulation of the α- 
secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J 23:1643–54 [PubMed: 
19144697] 
133. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. 2011 A randomized pilot clinical trial of 
the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch. Neurol 68:45–50 
[PubMed: 20837824] 
134. Bagheri M, Joghataei MT, Mohseni S, Roghani M. 2011 Genistein ameliorates learning and 
memory deficits in amyloid β(1–40) rat model of Alzheimer’s disease. Neurobiol. Learn. Mem 
95:270–76 [PubMed: 21144907] 
135. Zaman Z, Roche S, Fielden P, Frost PG, Niriella DC, Cayley AC. 1992 Plasma concentrations of 
vitamins A and E and carotenoids in Alzheimer’s disease. Age Ageing 21:91–94 [PubMed: 
1575097] 
136. Hargis KE, Blalock EM. 2017 Transcriptional signatures of brain aging and Alzheimer’s disease: 
What are our rodent models telling us? Behav. Brain Res 322:311–28 [PubMed: 27155503] 
137. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, et al. 2010 Neuronal gene expression 
in non-demented individuals with intermediate Alzheimer’s disease neuropathology. Neurobiol. 
Aging 31:549–66 [PubMed: 18572275] 
138. Jeandel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin F, Cuny G. 1989 Lipid peroxidation 
and free radical scavengers in Alzheimer’s disease. Gerontology 35:275–82 [PubMed: 2630382] 
139. Jimenez-Jimenez FJ, Molina JA, de Bustos F, Orti-Pareja M, Benito-Leon J, et al. 1999 Serum 
levels of β-carotene, α-carotene and vitamin A in patients with Alzheimer’s disease. Eur. J. 
Neurol 6:495–97 [PubMed: 10362906] 
140. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT. 1999 Plasma chain-breaking 
antioxidants in Alzheimer’s disease, vascular dementia and Parkinson’s disease. QJM 92:39–45 
[PubMed: 10209671] 
141. Bourdel-Marchasson I,Delmas-Beauvieux MC,Peuchant E,Richard-Harston S, Decamps A,et al. 
2001 Antioxidant defences and oxidative stress markers in erythrocytes and plasma from 
normally nourished elderly Alzheimer patients. Age Ageing 30:235–41 [PubMed: 11443025] 
Moutinho et al. Page 21
Annu Rev Pharmacol Toxicol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
142. Mullan K, Williams MA, Cardwell CR, McGuinness B, Passmore P, et al. 2017 Serum 
concentrations of vitamin E and carotenoids are altered in Alzheimer’s disease: a case-control 
study. Alzheimers Dement 3:432–39
143. Elstner M, Morris CM, Heim K, Bender A, Mehta D, et al. 2011 Expression analysis of 
dopaminergic neurons in Parkinson’s disease and aging links transcriptional dysregulation of 
energy metabolism to cell death. Acta Neuropathol 122:75–86 [PubMed: 21541762] 
144. Miller RM, Kiser GL, Kaysser-Kranich TM, Lockner RJ, Palaniappan C, Federoff HJ. 2006 
Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson’s disease. 
Neurobiol. Dis 21:305–13 [PubMed: 16143538] 
145. Kim JH, Hwang J, Shim E, Chung EJ, Jang SH, Koh SB. 2017 Association of serum carotenoid, 
retinol, and tocopherol concentrations with the progression of Parkinson’s disease. Nutr. Res. 
Pract 11:114–20 [PubMed: 28386384] 
146. Labadorf A, Hoss AG, Lagomarsino V, Latourelle JC, Hadzi TC, et al. 2015 RNA sequence 
analysis of human Huntington disease brain reveals an extensive increase in inflammatory and 
developmental gene expression. PLOS ONE 10:e0143563 [PubMed: 26636579] 
147. Dangond F, Hwang D, Camelo S, Pasinelli P, Frosch MP, et al. 2004 Molecular signature of late-
stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. 
Physiol. Genom 16:229–39
148. Iwasaki Y, Ikeda K, Kinoshita M. 1995 Vitamin A and E levels are normal in amyotrophic lateral 
sclerosis. J. Neurol. Sci 132:193–94 [PubMed: 8543947] 
149. Batra R, Hutt K, Vu A, Rabin SJ, Baughn MW, et al. 2016 Gene expression signatures of sporadic 
ALS motor neuron populations. bioRxiv 038448 10.1101/038448
150. Testa G, Staurenghi E, Zerbinati C, Gargiulo S, Iuliano L, et al. 2016 Changes in brain oxysterols 
at different stages of Alzheimer’s disease: their involvement in neuroinflammation. Redox Biol 
10:24–33 [PubMed: 27687218] 
151. Wisniewski T, Newman K, Javitt NB. 2013 Alzheimer’s disease: brain desmosterol levels. J. 
Alzheimers Dis 33:881–88 [PubMed: 23042211] 
152. Bjorkhem I, Lovgren-Sandblom A, Leoni V, Meaney S, Brodin L, et al. 2013 Oxysterols and 
Parkinson’s disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid 
correlates with the duration of the disease. Neurosci. Lett 555:102–5 [PubMed: 24035896] 
153. Kreilaus F, Spiro AS, Hannan AJ, Garner B, Jenner AM. 2015 Brain cholesterol synthesis and 
metabolism is progressively disturbed in the R6/1 mouse model of Huntington’s disease: a 
targeted GC-MS/MSsterol analysis. J. Huntingtons Dis 4:305–18 [PubMed: 26639223] 
154. Abdel-Khalik J, Yutuc E, Crick PJ, Gustafsson JA, Warner M, et al. 2017 Defective cholesterol 
metabolism in amyotrophic lateral sclerosis. J. Lipid Res 58:267–78 [PubMed: 27811233] 
155. Nasaruddin ML, Holscher C, Kehoe P, Graham SF, Green BD. 2016 Wide-ranging alterations in 
the brain fatty acid complement of subjects with late Alzheimer’s disease as detected by GC-MS. 
Am. J. Transl. Res 8:154–65 [PubMed: 27069549] 
156. Abbott SK, Jenner AM, Spiro AS, Batterham M, Halliday GM, Garner B. 2015 Fatty acid 
composition of the anterior cingulate cortex indicates a high susceptibility to lipid peroxidation in 
Parkinson’s disease. J. Parkinsons Dis 5:175–85 [PubMed: 25613350] 
157. Ilieva EV, Ayala V, Jove M, Dalfo E, Cacabelos D, et al. 2007 Oxidative and endoplasmic 
reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain 130:3111–23 [PubMed: 
17716997] 
158. Lin L, Park JW, Ramachandran S, Zhang Y, Tseng YT, et al. 2016 Transcriptome sequencing 
reveals aberrant alternative splicing in Huntington’s disease. Hum. Mol. Genet 25:3454–66 
[PubMed: 27378699] 
Moutinho et al. Page 22
Annu Rev Pharmacol Toxicol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
NR mechanisms of action. (a) NRs of the type II family, namely RARs, LXRs, and PPARs, 
bind to DNA-specific NRE within the promoters of their target genes as obligate 
heterodimers with RXR and regulate gene expression. In the absence of ligand binding, 
these NR heterodimers associate with corepressor complexes such as NCoR/SMRT and 
HDAC3, which results in the repression of target genes. Conformational changes upon 
binding of NR ligands result in the dismissal of the corepressor complex and the association 
of NRs with coactivators, resulting in the transcriptional activation of target gene expression. 
(b) NR monomers such as PPARγor LXR can undergo sumoylation upon ligand binding and 
recruit a NCor/SMRT corepressor complex inhibiting gene expression, such as NF-κB-
regulated proinflammatory genes. (c) Unlike RARs, PPARs, and LXRs, Nurr1 can directly 
bind to response elements not only as RXR:Nurr1 heterodimers but also as monomers or 
homodimers and activate target genes. Nurr1 homodimers bind to NurRE, while RXR:Nurr1 
heterodimers bind to DR5. Sumoylation of Nurr1 leads to monomerization, and these 
monomers can activate NBRE, or interact with p65 on NF-κB RE and recruit the 
corepressor CoREST, inhibiting the expression of NF-κBregulated proinflammatory genes. 
Abbreviations: CoREST, REST corepressor; DR5, direct repeats separated by five 
nucleotides; HDAC3, histone deacetylase 3; LXR, liver X receptor; NBRE, NGFI-B 
responsive elements; NCoR, nuclear receptor corepressor; NF-κB, nuclear factor-κB; NF-
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κB RE, NF-κB response elements; NR, nuclear receptor; NRE, nuclear receptor response 
elements; Nurr1, nuclear receptor related-1 protein; NurRE, Nur response element; PPAR, 
peroxisome proliferator-activated receptor; RAR: retinoic acid receptor; RXR, retinoid X 
receptor; SMRT, silencing mediator of retinoid and thyroid hormone receptors. Original and 
modified images from somersault:1824 (http://www.somersault1824.com).
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Figure 2. 
NR activation in neurodegenerative diseases. Several natural and synthetic ligands of NRs 
exert beneficial effects in different neurodegenerative disease models. The activation of NRs 
counteracts pathological mechanisms that are common across neurodegenerative diseases, 
such as inflammation and neuronal dysfunction, and rescues several compromised biological 
functions, including mitochondrial function and protein homeostasis. The beneficial effect of 
NR ligands in neurodegenerative diseases relies on the combination of the different 
mechanisms. (a) NRs exert a neuroprotective effect by stimulating neurogenesis, dendritic 
arborization, and synaptic function. (b) Neuroprotection is also a consequence of other 
mechanisms, including a decrease in microglia activation and inflammation. (c) 
Additionally, NR activation preserves the mitochondrial function and the induced anti-
oxidative machinery, reducing the production of ROS and apoptosis. (d) NRs have also been 
known to regulate the production of pathological proteins and stimulate the clearance of 
aggregates of these proteins, such as Aβ. Abbreviations: NR, nuclear receptor; ROS, reactive 
oxygen species; RXR, retinoid X receptor. Original and modified images from somersault:
1824 (http://www.somersault1824.com).
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Figure 3. 
RAR signaling deficiency in the progression of neurodegenerative diseases. Several lines of 
evidence suggest that RAR activation mediates neuroprotection in the context of 
neurodegenerative diseases, and the lack of RAR signaling could play a major role in the 
progression or pathogenesis of this type of disorder. Across several neurodegenerative 
diseases, there is evidence that points to a reduction in the availability of RA, the 
endogenous RAR ligand, which could underlie the repression of RAR activation in the brain. 
Considering the analysis of tissue from patients, this reduced RA availability could be due to 
low levels of its precursor, vitamin A, but also because of a reduced expression of the 
enzymes responsible for its synthesis, such as Raldh. Therefore, therapeutic strategies aimed 
at particular targets (red dots) to normalize retinoid signaling, such as the activation of 
enzymes responsible for RA synthesis, the inhibition of RA metabolism, or directly 
activating RAR with synthetic agonists, may be of utility. Abbreviations: CYP26, retinoic 
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acid 4- hydroxylase; RA, all-trans-retinoic acid; Raldh, retinaldehyde dehydrogenase; RAR, 
retinoic acid receptor; RXR, retinoid X receptor. Original and modified images from 
somersault:1824 (http://www.somersault1824.com).
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Table 1
Ligands of nuclear receptors that exhibit beneficial effects in preclinical models of neurodegenerative diseases, 
and their current status in clinical trials
Nuclear receptors Ligands Disease Models Clinical trials References
RXR Bexarotene AD Genetic models: 
5XFAD, APP/PS1, 
APP/PS1–21, 
Tg2576 mice
Pilot trial: no clinical 
benefit
47, 49, 54, 55
PD Toxin-induced 
neurotoxicity: 6-
OHDA rats
None 45
HD Genetic models: 
N171–82Q mice
None 60
ALS Genetic models: 
SOD1G93A mice
None 61
BRF110 PD Toxin-induced 
neurotoxicity: MPTP 
and 6-OHDA mice
None 57
IRX4204 PD Toxin-induced 
neurotoxicity (in 
vivo): 6-OHDA rats
Phase 1: no results 
posted 58
a
RAR Tamibarotene (Am80) AD Genetic models: 
APP23 mice
Phase 2: no results 
posted 66
b
Acitretin AD Genetic models: 
APP/PS1–21 mice
Phase 2: acitretin 
drives 
nonamyloidogenic 
APP processing in 
human patients
69, 132
RA-loaded polymeric nanoparticles PD Toxin-induced 
neurotoxicity: MPTP 
mice
None 70
9-cis-retinoic acid PD Toxin-induced 
neurotoxicity (in 
vivo): 6-OHDA rats
None 71
LXR TO901317 AD Genetic models: 
Tg2576, APP23, 
APP/PS1, 3xTg mice
None 49
GW3965 AD Genetic models: 
Tg2576, APP23, 
APP/PS1, 3xTg mice
None 49
GW3965 PD Toxin-induced 
neurotoxicity: MPTP 
mice
None 85
PPARs Pioglitazone AD Genetic models: 
Tg2576, 5XFAD, 
APP/PS1, 3xTg, 
APPV7171 mice and 
several others
Phase 2: no efficacy 
demonstrated on 
clinical outcomes
49, 101, 133
PD Toxin-induced 
neurotoxicity: 
MPTP, 6-OHDA 
rodents
Phase 2: unlikely to 
modify disease 
progression
107–109, 112, 114
ALS Genetic models: 
SOD1G93A mice, 
TDP and FUS 
Drosophila
Pilot trial: failed as an 
add-on to riluzole and 
tretinoin therapy
78, 121–123, 126
Annu Rev Pharmacol Toxicol. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Moutinho et al. Page 29
Nuclear receptors Ligands Disease Models Clinical trials References
Phase 2: failed as an 
add-on to riluzole 
therapy
Rosiglitazone AD Genetic models: 
Tg2576, 5XFAD, 
APP/PS1
Phase 3: fail as 
monotherapy in 
cognition or global 
function
Phase 3: fail as an add-
on to acetylcholine 
esterase inhibitor
49, 101, 103, 104
PD Toxin-induced 
neurotoxicity MPTP, 
6-OHDA animals
None 107, 108
HD Genetic models: 
N171–82Q, R6/2 
mice
None 117, 118
Genistein AD Hippocampal 
injection of Aβ 
peptides in rats
Genetic models: 
APP/PS1 mice
Phase 1: recruiting 134
Nurr1 Amodiaquine PD Toxin-induced 
neurotoxicity: 6-
OHDA mice
None 128
Chloroquine PD Toxin-induced 
neurotoxicity: 6-
OHDA mice
None 128
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; APP, amyloid precursor protein; HD, Huntington’s disease; PD, 
Parkinson’s disease; RA, all-trans-retinoic acid.
aNCT02438215.
bNCT01120002.
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